Press release
Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data | Report by Fact.MR
To remain ‘ahead’ of your competitors, request for a sample @
https://www.factmr.com/connectus/sample?flag=S&rep_id=2268
Carbapenem-resistant Enterobacteriaceae Testing Market: Segmentation
Based on test type, the global Carbapenem-resistant Enterobacteriaceae Testing Market is segmented as:
Modified Hodge Carbapenem-resistant Enterobacteriaceae Testing
Minimal inhibitory concentration Carbapenem-resistant Enterobacteriaceae Testing
Other types of Carbapenem-resistant Enterobacteriaceae Testing
Based on end users, the global Carbapenem-resistant Enterobacteriaceae Testing Market is segmented as:
Hospitals
Ambulatory Surgical Centers
Intensive Care Units
Clinics
Nursing Homes
Long Term Acute Care Centers
Others
Based on geography, the global Carbapenem-resistant Enterobacteriaceae Testing Market is segmented as:
North America
Latin America
Europe
CIS & Russia
Japan
APEJ
Middle East & Africa
Carbapenem-resistant Enterobacteriaceae Testing
Market: Overview
In Carbapenem-resistant Enterobacteriaceae Testing, Modified Hodge tests are anticipated to be one of the leading test types for Carbapenem-resistant enterobacteriaceae testing because of high accuracy of test results. These tests are easy to perform and can be performed in a routine laboratory, which makes them more feasible and thus, one of the leading test types in Carbapenem-resistant enterobacteriaceae testing market. Molecular testing detects the resistance mechanism whereas phenotypic tests detect the in-vitro activity of carbapenemase enzyme. Healthcare settings, such as nursing homes and acute care centers, where constant medical care is required for a longer duration of time are more prone to CRE and thus, the demand for Carbapenem-resistant enterobacteriaceae testing is higher in these settings.
Request Full Report With TOC@
https://www.factmr.com/connectus/sample?flag=T&rep_id=2268
Carbapenem-resistant Enterobacteriaceae Testing Market: Key Players
Some of major participants operating in the Carbapenem-resistant Enterobacteriaceae Testing market are TBA, SolGent Co., Ltd., ELITechGroup, ALIFAX S.r.l. and bioMérieux, Inc.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The report covers exhaustive analysis on:
Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain
Request Customized Report As Per Your Requirements@
https://www.factmr.com/connectus/sample?flag=RC&rep_id=2268
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com
Research Insight:https://www.factmr.com/report/2268/carbapenem-resistant-enterobacteriaceae-testing-market
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data | Report by Fact.MR here
News-ID: 2255830 • Views: …
More Releases from Fact.MR
Muscle Stimulators Market is Valued USD 1.43 billion in 2025 | Key players inclu …
The global muscle stimulators market is set for significant expansion, with its valuation expected to increase from USD 1.43 billion in 2025 to USD 2.92 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of 7.4% over the forecast period from 2025 to 2035. The market's robust trajectory is driven by rising awareness of health and fitness, technological advancements in rehabilitation devices, and the increasing prevalence…
Sleeping Aids Market to extend USD 131.3 Billion by 2035 | Abecca Healthcare, Be …
Fact.MR today unveiled its latest report on the Sleeping Aids Market, forecasting robust growth amid escalating sleep disorders, heightened stress levels, and a global push for restorative wellness solutions. Valued at USD 78.3 billion in 2025, the global market is projected to expand at a compound annual growth rate (CAGR) of 5.3%, reaching USD 131.3 billion by 2035. This trajectory reflects the market's pivotal role in addressing widespread insomnia, sleep…
Marketing Automation Market Will Hit USD 26.68 Billion by 2034 | Adobe; Hubspot; …
The global marketing automation market is experiencing robust growth, valued at USD 6.83 billion in 2024 and forecasted to reach USD 26.68 billion by 2034. This expansion reflects a compound annual growth rate (CAGR) of 14.6% over the forecast period from 2024 to 2034. The surge is primarily driven by the escalating demand for targeted advertising, enhanced user retention, and data-backed strategies in digital marketing channels. As internet penetration and…
Integrated Workplace Management System Market to Reach USD 10.6 Billion by 2034, …
The global Integrated Workplace Management System (IWMS) market is experiencing significant growth, with projections indicating an increase from approximately USD 4 billion in 2024 to USD 10.6 billion by 2034, reflecting a compound annual growth rate (CAGR) of 10.2% over the period from 2025 to 2034. This expansion is attributed to the rising demand for automation in facility management, the adoption of digital workplace solutions, and the need for efficient…
More Releases for Enterobacter
Klebsiella Infections Pipeline Insight 2025: Innovative Antibiotics and Novel Th …
DelveInsight's "Klebsiella Infections - Pipeline Insight, 2025" explores the evolving landscape of therapies aimed at tackling Klebsiella pneumoniae and related species, which are major culprits behind hospital-acquired infections, including pneumonia, bloodstream infections, and urinary tract infections. The rise of multidrug-resistant (MDR) and carbapenem-resistant strains has made Klebsiella a critical public health challenge with high morbidity and mortality.
The pipeline is advancing with novel β-lactam/β-lactamase inhibitor combinations, next-generation aminoglycosides, siderophore cephalosporins, and…
Multidrug-Resistant Gram-Negative Infections Pipeline Insight, 2025: Tackling Es …
DelveInsight's "Multidrug-Resistant Gram-Negative Infections - Pipeline Insight, 2025" report delivers an in-depth analysis of the dynamic R&D landscape targeting MDRGN pathogens such as Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacter species. The report covers over 10 promising investigational therapies in various stages of development, including β-lactam/β-lactamase inhibitor combinations, novel tetracyclines, polymyxins, and non-traditional antibacterial agents.
As antimicrobial resistance surges globally, pharma and biotech innovators are shifting focus toward new mechanisms…
Hospital-acquired and Ventilator-associated Bacterial Pneumonia Treatment Market …
DelveInsight's "Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Hospital-acquired and Ventilator-associated Bacterial Pneumonia, historical and forecasted epidemiology as well as the HABP/VABP market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover Key Insights into the Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market with DelveInsight's In-Depth Report @ Hospital-acquired and Ventilator-associated…
Klebsiella Infections Pipeline: 7+ Companies Targeting Multi-Drug Resistance wit …
With rising concerns over antibiotic-resistant Klebsiella strains, more than 7 companies are actively developing cutting-edge therapies, including Nosopharm, Debiopharm, and Locus Biosciences. The Klebsiella infections pipeline spans novel antibiotics, monoclonal antibodies, bacteriophage therapy, and immunotherapies. Efforts are particularly focused on carbapenem-resistant Klebsiella pneumoniae (CRKP), an urgent threat per WHO. The pipeline reflects a crucial shift toward precision antimicrobials and host-directed therapies to overcome resistance and reduce mortality in nosocomial infections.
DelveInsight's…
Hospital-acquired and Ventilator-associated Bacterial Pneumonia Treatment Market …
DelveInsight's "Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Hospital-acquired and Ventilator-associated Bacterial Pneumonia, historical and forecasted epidemiology as well as the HABP/VABP market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover Key Insights into the Hospital-acquired and Ventilator-associated Bacterial Pneumonia Market with DelveInsight's In-Depth Report @ Hospital-acquired and Ventilator-associated…
Enterobacteriaceae Infection Drug: A Guide to Understanding the Process
MARKET INTRODUCTION
Enterobacteriaceae are a large family of different types of germs (bacteria) that commonly cause infections in healthcare settings. Examples of germs in the Enterobacteriaceae family include Escherichia coli (E. coli) and Klebsiella pneumoniae.
MARKET DYNAMICS
Rising prevalence of Enterobacteriaceae infectious diseases, For instance, in 2021, CRE caused an estimated 13,100 infections in hospitalized patients, and 1,100 estimated deaths in the United States increasing modes of spread of the infectious disease and…
